MedPath

Research on HER2 expression in metastatic colorectal cancer

Not Applicable
Conditions
Colorectal cancer
Registration Number
JPRN-UMIN000018786
Lead Sponsor
Japan Clinical Cancer Research Organization
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

(1) Patients who received neoadjuvant chemotherapy . (2) Patients who are regarded as inadequate for study enrollment by investigators.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The HER2-positive ratio by the IHC method, the FISH method and the HERmark method
Secondary Outcome Measures
NameTimeMethod
To evaluate the sensitivity of the HERmark method. To examine the relationship between the HER2 expression and the background factor.
© Copyright 2025. All Rights Reserved by MedPath